Rein Therapeutics Inc Total Liabilities
Rein Therapeutics Inc total liabilities. Based on the latest financial reports, Rein Therapeutics Inc (RNTX) has total liabilities worth $55.77 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Rein Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Rein Therapeutics Inc (2015–2025)
Total liabilities of Rein Therapeutics Inc from 2015 to 2025. This chart illustrates how Rein Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Rein Therapeutics Inc to see how much of total assets are deployed in long-term investments.
Rein Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Rein Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AurosTechnology Inc.
KQ:322310
|
Korea | ₩58.38 Billion |
|
Dmg Blockchain Solutions Inc
V:DMGI
|
Canada | CA$24.71 Million |
|
Tex Cycle Technology M Bhd
KLSE:0089
|
Malaysia | RM91.82 Million |
|
Wp Energy Public Company Limited
BK:WP
|
Thailand | ฿5.52 Billion |
|
Comet Ridge Ltd
AU:COI
|
Australia | AU$47.06 Million |
|
Grupo Mexicano de Desarrollo S.A.B
MX:GMD
|
Mexico | MX$3.45 Billion |
|
Yunsa Yunlu Sanayi ve Ticaret AS
IS:YUNSA
|
Turkey | TL1.52 Billion |
|
Mandom Indonesia Tbk
JK:TCID
|
Indonesia | Rp530.70 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Rein Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Rein Therapeutics Inc total assets.
Liquidity & Leverage Metrics
Rein Therapeutics Inc Total Liabilities Ratios Explained
Rein Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rein Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rein Therapeutics Inc (2015–2025)
The table below shows the annual total liabilities of Rein Therapeutics Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.24 Million | -51.24% |
| 2024-12-31 | $14.85 Million | -85.02% |
| 2023-12-31 | $99.12 Million | +2829.11% |
| 2022-12-31 | $3.38 Million | -26.07% |
| 2021-12-31 | $4.58 Million | +9.52% |
| 2020-12-31 | $4.18 Million | -59.91% |
| 2019-12-31 | $10.43 Million | -2.68% |
| 2018-12-31 | $10.71 Million | +119.01% |
| 2017-12-31 | $4.89 Million | -96.35% |
| 2016-12-31 | $133.83 Million | +33.48% |
| 2015-12-31 | $100.26 Million | -- |
About Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b a… Read more